E/M Coding Alert - 2003 Issue 18
Compliance: DOCS FACE THE MUSIC IN OIG PHARMA GUIDANCE
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare compliance update from the HHS Office of Inspector General addressing pharmaceutical manufacturer conduct and related fraud-and-abuse concerns. It is relevant to physicians, drugmakers, and other health care professionals who need to understand the general compliance risk areas discussed, including data integrity, business arrangements, interactions tied to marketing, and drug sample billing issues.
Why This Topic Matters
The article matters because it outlines compliance risks that can affect both pharmaceutical companies and providers, helping readers recognize areas of scrutiny under Medicare fraud-and-abuse enforcement.
What You Will Learn
- The main compliance risk themes highlighted in the OIG guidance
- Why pharmaceutical manufacturer guidance may also matter to physicians and other providers
- The general categories of business arrangements and interactions that raise concern
- How drug sample billing is treated in the compliance discussion
- Why safe harbor protection is mentioned in the context of these risks
Who Should Read This
- Physicians
- Pharmaceutical manufacturers
- Health care compliance professionals
- Medical practice administrators
- Revenue cycle and billing staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com